bioengineer.org /1 month ago

Platinum Chemotherapy, Not PARP Inhibitors, Emerges as the Main Driver of Blood Clone Expansion

New research shows carboplatin drives the expansion of TP53-mutant blood clones far more strongly than PARP inhibitors, while inherited homologous recombination deficiency unexpect...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.